Eloctate 250 Unit (Antihemophilic Factor (Recombinant Bdd), Fc Fusion Protein KIT) 250 UNIT

ELOCTATE 250 Unit is a recombinant antihemophilic factor used for treating hemophilia B. This intravenous kit helps manage bleeding episodes and prevent surgical bleeding.

Strength

250 UNIT

Pack Size

3ML

Manufacturer / TM Owner

SANOFI-AVENTIS CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ELOCTATE 250 Unit is primarily used for the control and prevention of bleeding episodes in patients with hemophilia B, a genetic disorder that affects blood clotting. It can also be used to manage bleeding during surgical procedures. This medication is designed to replace the missing clotting factor IX, which is essential for proper blood coagulation.

Side Effects

Common effects of ELOCTATE 250 Unit may include mild to moderate reactions at the injection site, such as redness or swelling. Some users might experience headache, nausea, or dizziness. These effects are generally temporary and should be discussed with a healthcare provider if they persist or worsen.

Precautions & Warnings

ELOCTATE 250 Unit should be handled with care, ensuring proper storage and administration as directed. It is important to inform your healthcare provider about any allergies or medical conditions before use. Always follow the prescribed guidelines for intravenous administration to minimize risks.

Avoid Interactions

ELOCTATE 250 Unit may interact with other medications, particularly those that affect blood clotting. It is advisable to consult with a healthcare provider before combining it with other treatments. Alcohol and certain supplements might also influence its effectiveness, so it's best to discuss all current medications with a professional.

Frequently Asked Questions

ELOCTATE 250 Unit is used to treat and prevent bleeding episodes in patients with hemophilia B.

ELOCTATE 250 Unit is administered intravenously, typically by a healthcare professional.

Common side effects may include mild reactions at the injection site, headache, nausea, or dizziness.

Yes, ELOCTATE 250 Unit can be used to manage bleeding during surgical procedures.

ELOCTATE 250 Unit should be used under the guidance of a healthcare provider, especially for patients with known allergies or medical conditions.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.